The company's chief executive pays for the Aduhelm fiasco, but who will want to step up and take on the Biogen challenge?
Aduhelm’s status as a commercial nonentity is confirmed, but what does the final coverage decision mean for follow-on amyloid-beta MAbs?
The Japanese group doubles down on lecanemab while somehow disentangling itself from the Aduhelm mess.
As Biogen continues to provide a case study in how not to launch a drug, Lilly and Roche insist the focus must remain on pivotal readouts.
But the pace of biopharma asset deals dips. Are the two trends related?
An analyst call over the Aduhelm coverage debacle sees Biogen threaten more cost cutting.
The US Centers for Medicare & Medicaid Services’ national coverage determination for Biogen’s Aduhelm makes for uncomfortable reading.
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.